VA-REGULA
As innovative digital verification methods continue to emerge, the debate around their reliability and effectiveness is heating up. Yet, a recent study “The New Imperative: Digital IDs” commissioned by Regula reveals the lasting importance of physical identity documents. Despite digital advances, a high percentage of organizations worldwide still depend on physical documents for verification.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240610221791/en/
According to Regula's study, digital IDs will not replace physical documents in the near future. The majority of companies globally rely on automation and biometrics for remote identity verification. (Graphic: Business Wire)
Current state. Companies employ various methods for identity verification, as shown in a Forrester Consulting study commissioned by Regula. 46% of respondents verify documents manually, even in remote scenarios involving video interviews or passport scan submission. Some companies have automated this process (53%) or switched to more secure forms of user authentication such as biometrics (54%) or multi-factor authentication (49%). A significant number of companies (44%) use third-party services that also often count on physical documents for thorough identity checks.
The Forrester Consulting study suggests that, while innovative digital verification methods are evolving, physical identity documents remain indispensable, ensuring reliable and trustworthy identity verification across various regulatory environments.
The reliance on physical documents is more pronounced in industries where security demands are stringent, such as Aviation (63%) and Finance (44%). Organizations from countries with rigid regulatory frameworks, including the US (50%) and Germany (49%), also stay true to manual checks.
Barriers to widespread Digital ID adoption. One of the obstacles on the road to broad adoption of the Digital ID concept is the lack of a general legislative framework for this form of identity proofing. 74% of respondents underscore the necessity for global digital ID standards and legislation to ensure interoperability of such IDs across borders.
However, with varied regional perspectives on identity and privacy (71%) and the technological disparity between countries (70%)—which are also named among the concerns—agreeing on these standards will be challenging. To address these difficulties, the situation requires collaborative innovation from authorities, businesses, and players in the identity verification (IDV) market.
The unified approach will become a pivot for establishing a consistently high reliability rate for Digital ID and contributing to the evolution of the IDV market. Sooner or later, this process will begin, since 72% of surveyed stakeholders believe the integration of digital IDs helps develop a robust global digital economy.
“Digital ID represents a significant change in how we approach identity verification, offering a brand-new dimension to our existing frameworks. However, the introduction of Digital ID as it now stands will not lead to the disruption of the IDV market. There are many signals indicating the need for long-term support of current identification types. While countries can adopt the new approach at their own pace domestically, a global shift to Digital IDs must be ubiquitous. This transition is hampered by various obstacles associated with political and economic issues, as well as a lack of universal public recognition of the technology. Eventually, obtaining Digital IDs will likely require presenting physical passports or ID cards, at least during the initial issuance stage. Even after the appearance of a complete ICAO standard for Digital ID, its worldwide adoption and the development of such a system will take time, and may involve considerable costs. Until this happens, we are just beginning to research the potential of this novelty,” said Ihar Kliashchou, Chief Technology Officer at Regula.
You can download the complete study with all the details for free here.
More on the topic:
- 42% of companies globally are ready to implement Digital ID.
- EU Digital Identity Wallet: Exploring Its Current Potential.
- 9 Identity Verification Trends Shaping 2024 for Forward-Thinking Businesses.
About Regula
Regula is a global developer of forensic devices and identity verification solutions. With our 30+ years of experience in forensic research and the largest library of document templates in the world, we create breakthrough technologies in document and biometric verification. Our hardware and software solutions allow over 1,000 organizations and 80 border control authorities globally to provide top-notch client service without compromising safety, security or speed.
Regula has been repeatedly named a Representative Vendor in the Gartner® Market Guide for Identity Verification.
Learn more at www.regulaforensics.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240610221791/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 10:00:00 CET | Press release
Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press release
First regulatory approval in the world for pimicotinib based on positive data from global Phase 3 MANEUVER studyIn MANEUVER, pimicotinib significantly improved objective response rate at week 25 (54% vs. 3.2% for placebo), while providing clinically meaningful and statistically significant improvements across all patient-reported outcomesWith longer-term follow-up, 3 out of 4 patients treated with pimicotinib achieved response per RECIST v1.1, and treatment continued to be well-toleratedApproval strengthens Merck’s leadership in rare tumors, with additional ongoing regulatory filings for pimicotinib underway globally Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity.
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
